Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Genital Neoplasms, Female | 4 | 2021 | 505 | 2.050 |
Why?
|
Uterine Cervical Neoplasms | 15 | 2022 | 1945 | 2.050 |
Why?
|
Cervical Intraepithelial Neoplasia | 2 | 2018 | 322 | 1.130 |
Why?
|
Robotics | 4 | 2013 | 855 | 0.820 |
Why?
|
Endometrial Neoplasms | 6 | 2013 | 1334 | 0.760 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2018 | 96 | 0.700 |
Why?
|
Gynecology | 5 | 2021 | 459 | 0.690 |
Why?
|
Cryotherapy | 1 | 2018 | 156 | 0.670 |
Why?
|
Laparoscopy | 5 | 2013 | 1990 | 0.620 |
Why?
|
Developing Countries | 4 | 2018 | 2675 | 0.620 |
Why?
|
Fellowships and Scholarships | 2 | 2021 | 964 | 0.590 |
Why?
|
Mentors | 1 | 2021 | 600 | 0.580 |
Why?
|
Ovarian Neoplasms | 13 | 2020 | 4727 | 0.550 |
Why?
|
Adnexal Diseases | 1 | 2015 | 103 | 0.510 |
Why?
|
Urologic Neoplasms | 1 | 2018 | 319 | 0.500 |
Why?
|
Medical Oncology | 6 | 2021 | 2070 | 0.490 |
Why?
|
Women's Health | 1 | 2021 | 1915 | 0.430 |
Why?
|
Vulnerable Populations | 1 | 2016 | 652 | 0.410 |
Why?
|
Pelvic Exenteration | 1 | 2010 | 20 | 0.410 |
Why?
|
Premenopause | 1 | 2015 | 1018 | 0.400 |
Why?
|
Health Resources | 1 | 2016 | 924 | 0.370 |
Why?
|
Hysterectomy | 3 | 2010 | 895 | 0.330 |
Why?
|
Pubic Symphysis | 1 | 2006 | 22 | 0.300 |
Why?
|
Vagina | 2 | 2009 | 778 | 0.270 |
Why?
|
Poverty | 1 | 2016 | 2573 | 0.260 |
Why?
|
Papillomavirus Infections | 1 | 2015 | 1472 | 0.260 |
Why?
|
Neoplasm Staging | 5 | 2013 | 11244 | 0.250 |
Why?
|
Vulvar Neoplasms | 1 | 2005 | 278 | 0.240 |
Why?
|
Saphenous Vein | 1 | 2005 | 527 | 0.230 |
Why?
|
Osteomyelitis | 1 | 2006 | 376 | 0.230 |
Why?
|
Female | 44 | 2022 | 377269 | 0.220 |
Why?
|
Healthcare Disparities | 2 | 2016 | 2987 | 0.220 |
Why?
|
Trophoblastic Tumor, Placental Site | 1 | 2000 | 14 | 0.200 |
Why?
|
Genes, BRCA1 | 4 | 2016 | 765 | 0.200 |
Why?
|
Mass Screening | 1 | 2015 | 5186 | 0.190 |
Why?
|
Feasibility Studies | 2 | 2019 | 4903 | 0.180 |
Why?
|
Education, Distance | 1 | 2022 | 251 | 0.180 |
Why?
|
Curriculum | 2 | 2021 | 3312 | 0.170 |
Why?
|
Cervix Uteri | 2 | 2019 | 574 | 0.160 |
Why?
|
Endometrial Hyperplasia | 1 | 1997 | 89 | 0.160 |
Why?
|
Intestinal Obstruction | 1 | 2000 | 415 | 0.160 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2010 | 4020 | 0.150 |
Why?
|
Humans | 45 | 2022 | 709431 | 0.150 |
Why?
|
Holography | 1 | 2016 | 81 | 0.150 |
Why?
|
Ablation Techniques | 1 | 2018 | 230 | 0.140 |
Why?
|
Progestins | 1 | 1997 | 284 | 0.140 |
Why?
|
Lymph Nodes | 2 | 2016 | 3431 | 0.140 |
Why?
|
Caribbean Region | 1 | 2015 | 174 | 0.140 |
Why?
|
Digestive System Surgical Procedures | 1 | 2000 | 567 | 0.140 |
Why?
|
Latin America | 1 | 2015 | 351 | 0.130 |
Why?
|
Neoplasm Recurrence, Local | 5 | 2010 | 8864 | 0.130 |
Why?
|
Genes, BRCA2 | 2 | 2016 | 585 | 0.130 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2006 | 1996 | 0.130 |
Why?
|
SEER Program | 4 | 2011 | 1556 | 0.130 |
Why?
|
Genes, Tumor Suppressor | 1 | 1998 | 1101 | 0.120 |
Why?
|
Uterine Neoplasms | 2 | 2000 | 1473 | 0.120 |
Why?
|
Urology | 1 | 2018 | 365 | 0.120 |
Why?
|
Genetic Counseling | 1 | 2016 | 577 | 0.120 |
Why?
|
Treatment Outcome | 8 | 2019 | 61963 | 0.110 |
Why?
|
Fallopian Tube Neoplasms | 1 | 2015 | 350 | 0.110 |
Why?
|
Staining and Labeling | 1 | 2016 | 1158 | 0.110 |
Why?
|
Electrosurgery | 1 | 1991 | 58 | 0.110 |
Why?
|
Germ-Line Mutation | 2 | 2001 | 1733 | 0.110 |
Why?
|
Cancer Care Facilities | 1 | 2014 | 417 | 0.110 |
Why?
|
Brachytherapy | 2 | 2016 | 1284 | 0.110 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2016 | 600 | 0.100 |
Why?
|
Specialization | 1 | 2016 | 789 | 0.100 |
Why?
|
Carcinoma | 2 | 2003 | 2330 | 0.100 |
Why?
|
Cisplatin | 1 | 2016 | 1663 | 0.100 |
Why?
|
Menorrhagia | 1 | 2009 | 53 | 0.090 |
Why?
|
World Health Organization | 1 | 2015 | 1276 | 0.090 |
Why?
|
Early Detection of Cancer | 3 | 2022 | 2842 | 0.090 |
Why?
|
Enzyme Inhibitors | 1 | 2020 | 3955 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 11269 | 0.090 |
Why?
|
Epidemics | 1 | 2014 | 481 | 0.090 |
Why?
|
Surgical Wound Dehiscence | 1 | 2009 | 214 | 0.090 |
Why?
|
Antineoplastic Agents | 3 | 2016 | 13763 | 0.090 |
Why?
|
HIV Infections | 3 | 2020 | 15439 | 0.080 |
Why?
|
Neurofibromatosis 1 | 1 | 2012 | 517 | 0.080 |
Why?
|
Lymphoma | 1 | 2016 | 1908 | 0.080 |
Why?
|
Rwanda | 2 | 2020 | 742 | 0.080 |
Why?
|
Inguinal Canal | 1 | 2005 | 72 | 0.070 |
Why?
|
Specialties, Surgical | 1 | 2011 | 386 | 0.070 |
Why?
|
Blood Loss, Surgical | 1 | 2010 | 666 | 0.070 |
Why?
|
Clinical Competence | 1 | 2021 | 4618 | 0.070 |
Why?
|
Middle Aged | 15 | 2018 | 215428 | 0.070 |
Why?
|
Intercellular Signaling Peptides and Proteins | 2 | 2020 | 1758 | 0.060 |
Why?
|
Adenocarcinoma, Papillary | 1 | 2003 | 86 | 0.060 |
Why?
|
Genetic Testing | 1 | 2016 | 3299 | 0.060 |
Why?
|
Hysterectomy, Vaginal | 1 | 2003 | 33 | 0.060 |
Why?
|
Cellulitis | 1 | 2005 | 235 | 0.060 |
Why?
|
Cameroon | 1 | 2022 | 60 | 0.060 |
Why?
|
Emergencies | 1 | 2009 | 1133 | 0.060 |
Why?
|
Retrospective Studies | 7 | 2020 | 71151 | 0.060 |
Why?
|
Neoplasm Seeding | 1 | 2003 | 90 | 0.060 |
Why?
|
Ultrasonography | 2 | 2015 | 5913 | 0.060 |
Why?
|
Adult | 13 | 2022 | 212298 | 0.060 |
Why?
|
Botswana | 2 | 2016 | 958 | 0.060 |
Why?
|
Vaginal Neoplasms | 1 | 2003 | 104 | 0.060 |
Why?
|
Referral and Consultation | 1 | 2015 | 3448 | 0.050 |
Why?
|
Paracrine Communication | 1 | 2003 | 285 | 0.050 |
Why?
|
Estrogen Antagonists | 1 | 2001 | 146 | 0.050 |
Why?
|
Ovariectomy | 1 | 2004 | 656 | 0.050 |
Why?
|
Lymphokines | 2 | 2003 | 971 | 0.050 |
Why?
|
Angiogenesis Inducing Agents | 1 | 2003 | 288 | 0.050 |
Why?
|
Aged, 80 and over | 5 | 2013 | 58752 | 0.050 |
Why?
|
Endothelial Growth Factors | 1 | 2003 | 695 | 0.050 |
Why?
|
Aged | 10 | 2016 | 162592 | 0.050 |
Why?
|
Life Expectancy | 2 | 2004 | 1119 | 0.050 |
Why?
|
Lymphedema | 1 | 2005 | 414 | 0.050 |
Why?
|
Lost to Follow-Up | 1 | 2020 | 99 | 0.050 |
Why?
|
Survival Analysis | 1 | 2013 | 10603 | 0.050 |
Why?
|
Chorionic Gonadotropin, beta Subunit, Human | 1 | 1999 | 76 | 0.050 |
Why?
|
Lymph Node Excision | 1 | 2005 | 1182 | 0.050 |
Why?
|
Cystadenocarcinoma, Serous | 1 | 2003 | 457 | 0.050 |
Why?
|
Human papillomavirus 18 | 1 | 2019 | 129 | 0.050 |
Why?
|
Adenocarcinoma | 2 | 2009 | 6462 | 0.040 |
Why?
|
Acyltransferases | 1 | 2020 | 317 | 0.040 |
Why?
|
Prognosis | 5 | 2003 | 29148 | 0.040 |
Why?
|
Human papillomavirus 16 | 1 | 2019 | 266 | 0.040 |
Why?
|
Drug Synergism | 2 | 2020 | 1890 | 0.040 |
Why?
|
Patient Satisfaction | 1 | 2010 | 3390 | 0.040 |
Why?
|
Estrogen Replacement Therapy | 1 | 2004 | 1181 | 0.040 |
Why?
|
Pregnancy | 4 | 2006 | 26811 | 0.040 |
Why?
|
Postoperative Care | 1 | 2004 | 1513 | 0.040 |
Why?
|
Hydatidiform Mole | 1 | 1999 | 274 | 0.040 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 1998 | 237 | 0.040 |
Why?
|
Wnt Proteins | 1 | 2020 | 735 | 0.040 |
Why?
|
Decision Support Techniques | 2 | 2004 | 2030 | 0.040 |
Why?
|
Hormone Replacement Therapy | 1 | 2001 | 737 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2016 | 17347 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 1 | 2001 | 1594 | 0.040 |
Why?
|
Lymphatic Metastasis | 1 | 2003 | 2992 | 0.040 |
Why?
|
Survival Rate | 3 | 2011 | 13363 | 0.030 |
Why?
|
Breast Neoplasms | 2 | 2001 | 19798 | 0.030 |
Why?
|
African Americans | 1 | 2011 | 5194 | 0.030 |
Why?
|
Remission Induction | 2 | 1999 | 2414 | 0.030 |
Why?
|
beta Catenin | 1 | 2020 | 1063 | 0.030 |
Why?
|
Forefoot, Human | 1 | 2014 | 32 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 1088 | 0.030 |
Why?
|
Patient Care Planning | 1 | 2000 | 933 | 0.030 |
Why?
|
Socioeconomic Factors | 3 | 2016 | 7740 | 0.030 |
Why?
|
Microspheres | 1 | 2016 | 799 | 0.030 |
Why?
|
Chickenpox | 1 | 1994 | 130 | 0.030 |
Why?
|
Papillomaviridae | 1 | 2019 | 1131 | 0.030 |
Why?
|
Interinstitutional Relations | 1 | 2014 | 250 | 0.030 |
Why?
|
Mutation | 2 | 2016 | 29242 | 0.030 |
Why?
|
Herpesvirus 3, Human | 1 | 1994 | 212 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2003 | 2723 | 0.030 |
Why?
|
Capacity Building | 1 | 2014 | 252 | 0.030 |
Why?
|
Infertility, Female | 1 | 1997 | 754 | 0.030 |
Why?
|
Hospitalization | 1 | 2011 | 9632 | 0.030 |
Why?
|
Biopsy, Fine-Needle | 1 | 2016 | 1063 | 0.030 |
Why?
|
Point-of-Care Systems | 1 | 2019 | 1104 | 0.030 |
Why?
|
Professional Practice Location | 1 | 2011 | 61 | 0.030 |
Why?
|
Chemotherapy, Adjuvant | 1 | 1999 | 3535 | 0.030 |
Why?
|
Pedigree | 1 | 1998 | 4720 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2003 | 4668 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2003 | 3884 | 0.020 |
Why?
|
Advisory Committees | 1 | 2014 | 757 | 0.020 |
Why?
|
Histamine Release | 1 | 1989 | 155 | 0.020 |
Why?
|
Follow-Up Studies | 4 | 2020 | 39394 | 0.020 |
Why?
|
Markov Chains | 2 | 2004 | 992 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2020 | 2963 | 0.020 |
Why?
|
Constriction, Pathologic | 1 | 2012 | 1015 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2000 | 5168 | 0.020 |
Why?
|
Viral Vaccines | 1 | 1994 | 629 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 34096 | 0.020 |
Why?
|
Comorbidity | 2 | 2016 | 10621 | 0.020 |
Why?
|
Patient Selection | 1 | 2000 | 4322 | 0.020 |
Why?
|
Registries | 1 | 2003 | 8019 | 0.020 |
Why?
|
Basophils | 1 | 1989 | 396 | 0.020 |
Why?
|
Plant Proteins | 1 | 1989 | 361 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4282 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2009 | 15035 | 0.020 |
Why?
|
Coronary Disease | 1 | 2001 | 6130 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2003 | 8733 | 0.020 |
Why?
|
Decision Making | 1 | 2000 | 3807 | 0.020 |
Why?
|
Neoplasms | 1 | 2014 | 20421 | 0.020 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2014 | 2169 | 0.020 |
Why?
|
Mice, Inbred C57BL | 2 | 2020 | 23044 | 0.020 |
Why?
|
Interleukin-1 | 1 | 1989 | 1304 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2016 | 7078 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 1991 | 1648 | 0.020 |
Why?
|
United States | 4 | 2011 | 67177 | 0.020 |
Why?
|
Lymphocytes | 1 | 1994 | 2822 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6830 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2020 | 15286 | 0.020 |
Why?
|
Age Factors | 2 | 2004 | 18954 | 0.020 |
Why?
|
Regression Analysis | 2 | 2006 | 6515 | 0.020 |
Why?
|
Adjuvants, Immunologic | 1 | 1989 | 958 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2020 | 17087 | 0.020 |
Why?
|
Nucleic Acid Synthesis Inhibitors | 1 | 2003 | 119 | 0.020 |
Why?
|
Immunoglobulin E | 1 | 1989 | 1475 | 0.020 |
Why?
|
Dactinomycin | 1 | 2003 | 329 | 0.020 |
Why?
|
Angiopoietin-1 | 1 | 2003 | 123 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2020 | 8101 | 0.010 |
Why?
|
Health Care Surveys | 1 | 2011 | 2503 | 0.010 |
Why?
|
Receptor, TIE-2 | 1 | 2003 | 188 | 0.010 |
Why?
|
Disease Progression | 1 | 2000 | 13298 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 1994 | 2895 | 0.010 |
Why?
|
Risk | 2 | 2006 | 9813 | 0.010 |
Why?
|
Angiopoietin-2 | 1 | 2003 | 169 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 22944 | 0.010 |
Why?
|
Allergens | 1 | 1989 | 1274 | 0.010 |
Why?
|
Actuarial Analysis | 1 | 2001 | 385 | 0.010 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2003 | 773 | 0.010 |
Why?
|
Cell Line, Transformed | 1 | 2003 | 997 | 0.010 |
Why?
|
Probability | 1 | 2006 | 2494 | 0.010 |
Why?
|
Boston | 1 | 2014 | 9409 | 0.010 |
Why?
|
Pericytes | 1 | 2003 | 260 | 0.010 |
Why?
|
Logistic Models | 2 | 2011 | 13622 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 2003 | 785 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2006 | 3599 | 0.010 |
Why?
|
Algorithms | 1 | 2000 | 13668 | 0.010 |
Why?
|
Quality of Life | 1 | 2000 | 11553 | 0.010 |
Why?
|
Health Status Disparities | 1 | 2011 | 1723 | 0.010 |
Why?
|
Biopsy | 1 | 1991 | 6786 | 0.010 |
Why?
|
Genes, Reporter | 1 | 2003 | 1614 | 0.010 |
Why?
|
Income | 1 | 2006 | 1787 | 0.010 |
Why?
|
Time Factors | 2 | 2016 | 41295 | 0.010 |
Why?
|
Stromal Cells | 1 | 2003 | 1385 | 0.010 |
Why?
|
Mice | 2 | 2020 | 80950 | 0.010 |
Why?
|
Risk Factors | 1 | 2003 | 70264 | 0.010 |
Why?
|
Laparotomy | 1 | 1999 | 476 | 0.010 |
Why?
|
Family Health | 1 | 2001 | 1313 | 0.010 |
Why?
|
CA-125 Antigen | 1 | 1998 | 279 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2011 | 12442 | 0.010 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2003 | 1628 | 0.010 |
Why?
|
Cohort Studies | 2 | 2011 | 39650 | 0.010 |
Why?
|
Recombinant Fusion Proteins | 1 | 2003 | 3901 | 0.010 |
Why?
|
Chickenpox Vaccine | 1 | 1994 | 82 | 0.010 |
Why?
|
Vaccines, Attenuated | 1 | 1994 | 330 | 0.010 |
Why?
|
Postmenopause | 1 | 2001 | 2406 | 0.010 |
Why?
|
Animals | 2 | 2020 | 170647 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2003 | 3482 | 0.010 |
Why?
|
Membrane Glycoproteins | 1 | 2003 | 3832 | 0.010 |
Why?
|
Male | 2 | 2022 | 351848 | 0.010 |
Why?
|
Poaceae | 1 | 1989 | 24 | 0.010 |
Why?
|
Pollen | 1 | 1989 | 89 | 0.010 |
Why?
|
Antigens, Plant | 1 | 1989 | 82 | 0.010 |
Why?
|
Medicare | 1 | 2006 | 5616 | 0.010 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 1989 | 406 | 0.010 |
Why?
|
Health Promotion | 1 | 2001 | 2180 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2001 | 5233 | 0.010 |
Why?
|
Reoperation | 1 | 1999 | 4155 | 0.010 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 1989 | 429 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2003 | 13351 | 0.010 |
Why?
|
Immunity, Cellular | 1 | 1994 | 1711 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 1994 | 4012 | 0.000 |
Why?
|
Models, Biological | 1 | 2003 | 9941 | 0.000 |
Why?
|
Analysis of Variance | 1 | 1994 | 6563 | 0.000 |
Why?
|
Diagnosis, Differential | 1 | 1999 | 13362 | 0.000 |
Why?
|
Lymphocyte Activation | 1 | 1994 | 5995 | 0.000 |
Why?
|
Recombinant Proteins | 1 | 1989 | 6946 | 0.000 |
Why?
|
Infant | 1 | 1994 | 34274 | 0.000 |
Why?
|
Child, Preschool | 1 | 1994 | 41195 | 0.000 |
Why?
|
Child | 1 | 1994 | 73998 | 0.000 |
Why?
|
Adolescent | 1 | 1994 | 85327 | 0.000 |
Why?
|